Skip to content

Sarepta Therapeutics

US · SRPT #2853 by market cap Listed 1970
13.33 -0.84 -5.93%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:54

Valuation each multiple against its own 5-year range

P/B ratio 1.13 Cheap vs history 2nd percentile
5-year average 10.17 · #153 of 514 in Biotechnology
P/E ratio -12.46 In line with history 43rd percentile
5-year average 23.56 · forward -52.72
P/S ratio 0.88 Cheap vs history 14th percentile
5-year average 6.96 · forward 1.22 · #20 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Sarepta Therapeutics (SRPT) 1.43B -10.33 0.93 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value19.79 Economic moatNone UncertaintyHigh

Trading 48.5% below Morningstar's fair value estimate.

Fair value

Sarepta Therapeutics Inc earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 19% discount to our quantitative fair value estimate of $19.79 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 80.0% lies in the top 40% compared with peers globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are cheap.

The firm's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 7.8%, a core component of profitability, sits in the top 30% globally. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:54:28 · For reference only, not investment advice and not tailored to your situation.

Sarepta Therapeutics discussion 0 comments

Add a comment